Rolixird 450 mg FC Tablet
PDF Leaflet Revision Date: 12 May 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of CMV retinitis in AIDS patients and prevention of CMV disease in solid organ transplant patients.
Dosage (summary)
900 mg twice daily for 21 days for induction; 900 mg once daily for maintenance.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
- Paediatric patients
Pregnancy & Breastfeeding
Not established for pregnancy; contraindicated in breastfeeding.
Key Drug Interactions
- Imipenem-cilastatin
- Zidovudine
- Didanosine
- Probenecid
Contraindications
- Hypersensitivity to valganciclovir or ganciclovir
- Severe leucopenia or thrombocytopenia
Common side effects
- Neutropenia
- Anaemia
- Diarrhoea
- Fatigue
Counselling Points
- Take with food
- Monitor blood counts regularly
- Use effective contraception during treatment
Serious warnings
- Risk of severe haematological toxicity
- Potential teratogen and carcinogen
Important Disclaimer
The Rolixird 450 mg FC Tablet professional information leaflet below is the property of Aurogen Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
